drugset
drugset / Trial / NCT01131234

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

NCT01131234 ↗

Phase 1 Completed 20 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I clinical trial is studying the side effects and best dose of giving gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with advanced solid tumors. Gamma-secretase inhibitor RO4929097 and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate also may stop the growth of tumor cells by blocking blood flow to the tumor.

Timeline

Start
2010-05
Primary completion
2014-09
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cediranib Small molecule — Oral
Subject RG4733 Small molecule — Oral

Indications

adult anaplastic ependymoma adult brainstem glioma adult glioblastoma anaplastic astrocytoma anaplastic oligodendroglioma colon carcinoma cutaneous melanoma exocrine pancreatic carcinoma female breast carcinoma giant cell glioblastoma gliosarcoma male breast carcinoma metastasis from malignant tumor of colon non-small cell lung carcinoma ovarian carcinoma ovarian germ cell tumor rectal carcinoma renal cell carcinoma uterine adnexa cancer